Hospital
Halifax Regional Medical Center INC
Halifax Regional Medical Center INC was paid $9.61M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoHALIFAX REGIONAL MEDICAL CENTER INC
ROANOKE RAPIDS, NC 27870
ROANOKE RAPIDS, NC 27870
33aNPI1346273943assigned 07/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.61M
24GClaims259,271
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#51 of 92
Median peer was paid$11.47M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,119 | $1.15M | |
| 2019 | 48,104 | $1.21M | |
| 2020 | 33,019 | $915K | |
| 2021 | 28,103 | $1.05M | |
| 2022 | 25,929 | $1.45M | |
| 2023 | 34,553 | $1.73M | |
| 2024incomplete | 43,444 | $2.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 18,559 | 17,557 | $2.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 23,248 | 22,276 | $1.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 9,937 | 9,418 | $1.61M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 6.6% | 4,091 | 3,885 | $638K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 5,963 | 5,580 | $230K |
| 71045 | Radiologic examination, chest; single view | 2.4% | 9,506 | 9,001 | $229K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 1,202 | 1,136 | $227K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 11,985 | 11,270 | $212K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 30,163 | 27,333 | $200K |
| 80053 | Comprehensive metabolic panel | 1.9% | 24,489 | 22,517 | $180K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 2,304 | 2,238 | $156K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 198 | 187 | $122K |
106 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,597 | $98K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,874 | $96K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,839 | $89K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,776 | $82K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,364 | $77K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,179 | $73K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,408 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,457 | $65K |
| 0225U | <1% | 177 | $64K | |
| J3490 | Unclassified drugs | <1% | 15,547 | $62K |
| 84484 | <1% | 7,416 | $60K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 984 | $56K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 70 | $46K |
| 81001 | <1% | 13,334 | $37K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 806 | $32K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 911 | $30K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 325 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,135 | $25K |
| 83690 | <1% | 3,780 | $25K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,721 | $22K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 42 | $18K |
| 81025 | <1% | 2,214 | $18K | |
| 82552 | <1% | 2,120 | $18K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 350 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,026 | $15K |
| 85730 | <1% | 3,162 | $12K | |
| Q0092 | Set-up portable x-ray equipment | <1% | 3,911 | $12K |
| 85610 | <1% | 4,085 | $10K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 72 | $9K |
| 83735 | <1% | 1,536 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,862 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,184 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 215 | $8K |
| 94760 | <1% | 1,864 | $7K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 93 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,204 | $7K |
| 82728 | <1% | 580 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 200 | $6K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 428 | $6K |
| 11043 | <1% | 109 | $5K | |
| 11045 | <1% | 129 | $5K | |
| 84466 | <1% | 496 | $5K | |
| 83605 | <1% | 518 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 96 | $4K |
| 87400 | <1% | 169 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 188 | $3K |
| 87040 | <1% | 216 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,261 | $3K |
| 83880 | <1% | 115 | $3K | |
| 83540 | <1% | 499 | $3K | |
| C1769 | Guide wire | <1% | 109 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 232 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 449 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 95 | $2K |
| 82607 | <1% | 151 | $1K | |
| 87631 | <1% | 21 | $1K | |
| 87088 | <1% | 159 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $1K |
| 82746 | <1% | 122 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 158 | $1K |
| 82565 | <1% | 311 | $1K | |
| 74018 | <1% | 13 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 94 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $970.19 |
| 81003 | <1% | 418 | $941.74 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 59 | $908.46 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 64 | $892.16 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 105 | $733.45 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 71 | $718.59 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 52 | $706.18 |
| 93041 | <1% | 73 | $629.91 | |
| 86850 | <1% | 76 | $567.95 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 198 | $528.27 |
| 87581 | <1% | 21 | $520.31 | |
| 87486 | <1% | 21 | $520.31 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 75 | $494.00 |
| 96376 | <1% | 42 | $481.02 | |
| 84100 | <1% | 143 | $445.47 | |
| 80076 | <1% | 87 | $399.54 | |
| 82077 | <1% | 137 | $397.99 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $388.12 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 215 | $383.50 |
| 96367 | <1% | 29 | $355.49 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 130 | $338.37 |
| 82962 | <1% | 93 | $321.10 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 24 | $287.67 |
| 80061 | Lipid panel | <1% | 30 | $275.08 |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $273.94 |
| 84165 | <1% | 60 | $271.45 | |
| 82378 | <1% | 14 | $211.76 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 157 | $210.64 |
| 87186 | <1% | 27 | $179.80 | |
| 87077 | <1% | 29 | $176.56 | |
| 83521 | <1% | 60 | $136.10 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $133.34 |
| 83615 | <1% | 37 | $126.04 | |
| 83010 | <1% | 18 | $108.40 | |
| 87807 | <1% | 14 | $104.93 | |
| 82247 | <1% | 13 | $85.41 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 45 | $71.85 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 28 | $59.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 13 | $28.29 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 280 | $25.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14 | $19.74 |
| 86900 | <1% | 14 | $12.85 | |
| 86901 | <1% | 14 | $12.85 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRELL, JASON (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Roanoke Valley Health Services INC | Roanoke Rapids, NC | $1.25M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.